HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca To Revisit Iressa Dosing Following Failed Survival Study

Executive Summary

Inappropriate dose selection is one issue AstraZeneca will examine following Iressa's failure to demonstrate a survival benefit in a Phase IV trial in refractory non-small cell lung cancer, CEO Tom McKillop indicated

Related Content

Iressa Gets Narrowed Indication Instead Of Withdrawal: New Model For FDA?
Tarceva Pancreatic Cancer Data Do Not Support Broad Use – ASCO Review
Iressa Casts Shadow Over Zarnestra Advisory Committee Review
Subgroup Analyses Need Confirmation In Independent Trials - Duke’s George
Iressa Data Likely To Be Revisited By FDA Oncologic Cmte. In June Or July
AstraZeneca Iressa Response Working, Company Says: Docs Move To Tarceva
Iressa Committee Will Not Vote On Market Withdrawal; FDA To Review Data
Genentech Plans Avastin/Tarceva Combo Filing; Avastin Warning Hurts Growth
AstraZeneca Cuts Sales Reps By Reducing PDI Contract; Will Others Follow?
AstraZeneca withdraws Iressa MAA





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts